As mentioned above, UDCA treatment in patients with primary biliary cirrhosis enhanced hepatic expression of Nrf2 and increased the protein abundance of the Nrf2 targets Trx and Trxr-1 [24,41]. The gene discussed is NFE2L2; the disease is primary biliary cholangitis.